TAG:
laboratory industry
Tamtron Plans Comeback After IMPATH’s Chapt. 11
By Robert Michel | From the Volume X No. 15 – November 10, 2003 Issue
CEO SUMMARY: It was only 21 months ago that IMPATH acquired Tamtron. Both companies had high expectations for the relationship. But with IMPATH now in Chapter 11 bankruptcy and facing an unclear future, Tamtron is now an attractive asset for potential buyers who want to enter the anatomic…
Specialty Laboratories, Enterix, Medicare, Blue Cross/Blue Shield Association
By Robert Michel | From the Volume X No. 15 – November 10, 2003 Issue
SPECIALTY LABORATORIES REPORTS THIRD QUARTER FINANCIAL PERFORMANCE THIRD QUARTER FINANCIAL REPORTS for Specialty Laboratories, Inc. show that the company is returning to a more normal routine, following the two unusual and unrelated events which hit it during 2002. Special…
Mergers Create Two Huge National Health Insurers
By Robert Michel | From the Volume X No. 15 – November 10, 2003 Issue
ANOTHER ROUND OF CONSOLIDATION among health insurers has created a new “biggest in the nation” company and boosted the size of the second largest health insurance company. On October 28, in separate announcements that were just 30 minutes apart, Anthem Inc. disclosed it would pa…
Chipping Away at Laboratory Reimbursement
By Robert Michel | From the Volume X No. 14 – October 20, 2003 Issue
PROPOSED NEW MEDICARE RULES by the Office of the Investigator General (OIG) dealing with “discriminatory billing practices” and “usual charges” should be seen as part of a larger trend. The government doesn’t have the money to pay for Medicare and Medicaid. Thus, it is expl…
OIG Moves to Address “Usual Charge” Issue
By Robert Michel | From the Volume X No. 14 – October 20, 2003 Issue
CEO SUMMARY: Federal regulators are taking another crack at defining “usual charges.” Language in the proposed rules published last month precisely defines which payers should be included in determining “usual charges” and what charge basis to use for specific payers. Once effecti…
No Disruptive Technology In Lab Industry’s Future
By Robert Michel | From the Volume X No. 14 – October 20, 2003 Issue
CEO SUMMARY: As new diagnostic technologies move through the development pipeline and into widespread clinical use, the scientific knowledge and skill sets needed by laboratory staff and management will change. The emphasis in laboratory medicine will evolve to include more molecular tech…
These Leaders in Lab Management Took Risks
By R. Lewis Dark | From the Volume X No. 13 – September 29, 2003 Issue
BY NOW THE NEWS IS GETTING OUT. Hospital laboratory administrators and pathologists are learning there now exists a management approach that cuts the average turnaround time from order to verified result by as much as 50% in as few as 12 weeks! If that’s not enough, this management approach will s…
Healthcare Premiums Climb At Double-Digit Rate for 2004
By Robert Michel | From the Volume X No. 13 – September 29, 2003 Issue
EXPECTATIONS that health insurance premiums will increase by an average of 12% to 15% for 2004 have captured plenty of media attention recently. Employers and health insurers are currently negotiating premiums for 2004. There is consensus among healthcare experts that 2004 will be the fourth consecu…
How “Lean” is Benefiting Early-Adopter Laboratories
By Robert Michel | From the Volume X No. 12 – September 8, 2003 Issue
CEO SUMMARY: First steps toward a radical change in clinical laboratory operations are under way in a handful of early-adopter laboratories. This movement is so new that little information about their successes can be published. But the early evidence is compelling. For those labs willing…
IMPATH Delisted by Nasdaq, Under Investigation by SEC
By Robert Michel | From the Volume X No. 12 – September 8, 2003 Issue
EFFECTIVE AUGUST 27, Nasdaq Stock Market, Inc. delisted the stock of IMPATH, Inc. Less than a week earlier, IMPATH had disclosed that it was under investigation by the Securities and Exchange Commission (SEC). IMPATH can truly be described as a comp…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized